Table Of ContentAdvances in Experimental Medicine and Biology 778
Editor
Pierre Busson
Nasopharyngeal
Carcinoma
Keys for Translational Medicine and Biology
Nasopharyngeal Carcinoma
ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
Editorial Board:
NATHAN BACK, State University of New York at Buffalo
IRUN R. COHEN, The Weizmann Institute of Science
ABEL LAJTHA, N.S. Kline Institute for Psychiatric Research
JOHN D. LAMBRIS, University of Pennsylvania
RODOLFO PAOLETTI, University of Milan
Recent Volumes in this Series
Volume 770
TRIM/RBCC PROTEINS
Germana Meroni
Volume 771
DIABETES: AN OLD DISEASE, A NEW INSIGHT
Shamim I. Ahmad
Volume 772
TUMOR MICROENVIRONMENT AND CELLULAR STRESS
Constantinos Koumenis, Amato J. Giaccia, Ester Hammond
Volume 773
CANCER BIOLOGY AND THE NUCLEAR ENVELOPE
Eric C. Schirmer and Jose de las Heras
Volume 774
MiRNA CANCER REGULATION - ADVANCED CONCEPTS, BIOINFORMATICS
AND SYSTEMS BIOLOGY TOOLS
Ulf Schmitz, Olaf Wolkenhauer and Julio Vera
Volume 775
TAURINE 8: THE NERVOUS SYSTEM, IMMUNE SYSTEM, DIABETES
AND THE CARDIOVASCULAR SYSTEM
Abdeslem El Idrissi and William J. L’Amoreaux
Volume 776
TAURINE 8: NUTRITION AND METABOLISM, PROTECTIVE ROLE, AND ROLE
IN REPRODUCTION, DEVELOPMENT, AND DIFFERENTIATION
Abdeslem El Idrissi and William J. L’Amoreaux
Volume 777
PROMININ-1 (CD133): NEW INSIGHTS ON STEM & CANCER STEM CELL BIOLOGY
Denis Corbeil
Volume 778
NASOPHARYNGEAL CARCINOMA: KEYS FOR TRANSLATIONAL MEDICINE
AND BIOLOGY
Pierre Busson
A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume
immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact
the publisher.
Nasopharyngeal Carcinoma
Keys for Translational Medicine and Biology
Edited by
Pierre Busson, MD, PhD
Université Paris-Sud 11, CNRS and Institut de Cancérologie Gustave Roussy,
UMR 8126, Villejuif, France
Springer Science+Business Media, LLC
Landes Bioscience
Springer Science+Business Media, LLC
Landes Bioscience
Copyright ©2013 Landes Bioscience and Springer Science+Business Media, LLC
All rights reserved.
No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical,
including photocopy, recording, or any information storage and retrieval system, without permission in writing
from the publisher, with the exception of any material supplied specifically for the purpose of being entered
and executed on a computer system; for exclusive use by the Purchaser of the work.
Springer Science+Business Media, LLC, 233 Spring Street, New York, New York 10013, USA
http://www.springer.com
Please address all inquiries to the publishers:
Landes Bioscience, 1806 Rio Grande, Austin, Texas 78701, USA
Phone: 512/ 637 6050; FAX: 512/ 637 6079
http://www.landesbioscience.com
The chapters in this book are available in the Madame Curie Bioscience Database.
http://www.landesbioscience.com/curie
Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology, edited by Pierre Busson.
Landes Bioscience / Springer Science+Business Media, LLC dual imprint / Springer series: Advances in
Experimental Medicine and Biology.
ISBN 978-1-4614-5946-0
While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage
of equipment and devices, as set forth in this book, are in accord with current recommenda tions and practice
at the time of publication, they make no warranty, expressed or implied, with respect to material described
in this book. In view of the ongoing research, equipment development, changes in governmental regulations
and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully
review and evaluate the information provided herein.
Library of Congress Cataloging-in-Publication Data
Nasopharyngeal carcinoma : keys for translational medicine and biology / edited by Pierre Busson.
p. ; cm. -- (Advances in experimental medicine and biology, v.778)
Includes bibliographical references and index.
ISBN 978-1-4614-5946-0 (alk. paper)
I. Busson, Pierre, 1956- II. Series: Advances in experimental medicine and biology ; v. 778. 0065-2598
[DNLM: 1. Nasopharyngeal Neoplasms--diagnosis. 2. Nasopharyngeal Neoplasms--therapy. W1 AD559
v.778 2013 / WV 410]
616.99’42--dc23
2012036817
DEDICATION
To my wife, Hélène, for her love, unflagging support and tireless dedication
v
PREFACE
Although listed as a rare cancer in a majority of countries, nasopharyngeal carcinoma
(NPC) has a high incidence and appears as a serious public health problem in several
highly populated areas of Southeast Asia and to a lesser extent in North Africa. Worldwide,
its incidence rates at 85,000 new cases per year (Globocan 2008). Thus, in terms of
incidence, among human virus-associated cancers, NPC ranks third behind liver and
cervix carcinoma (750,000 and 530,000, respectively). In 2008, the mortality rate of
NPC was still about 51,000 per year worldwide (Globocan).
NPC is a multifactorial disease related to dietary, viral and genetic factors. Despite
fascinating biological characteristics, NPC has long been outside from the mainstream
of cancer research for both scientific and socio-economical reasons. It is noteworthy that
biological investigations have long been hampered by the paucity of laboratory models
and the lack of data on premalignant states. However, recently, in several high incidence
countries, strong economic growth and rapid progress in health care has propelled NPC
onto the front stage of cancer research, worldwide. Simultaneously, in other places,
the identification of head and neck cancers associated to human papilloma viruses has
renewed interest for NPC as a proxy model of viral carcinogenesis.
As explained in the title, this book intends to contribute to “translational medicine and
biology”. By this, we mean a bi-directional process whose aim is to develop knowledge
from basic science towards diagnostic and therapeutic applications and reciprocally
to raise new questions for basic scientists. One general requirement for translational
research is to establish a multidisciplinary knowledge base shared by the actors of various
specialties. This is precisely the aim of the 12 chapters of this book. It will be useful for
scientists, including PhD students, who want to become more familiar with the main
concepts of NPC pathology, medical imaging and current therapeutics. Conversely,
medical doctors who want to update their knowledge of NPC biology will benefit from
chapters on viral and cellular oncogenesis and various aspects of host-tumor interactions.
Chapters 1 and 2 present the main concepts used for clinical and histological
identification and classification of NPCs. Following this introductory part, we move to
Chapter 3 dealing with all aspects of NPC epidemiology in a concise and comprehensive
manner. Chapters 4, 5 and 6 review most aspects of NPC oncogenesis including virus/
vii
viii PREFACE
cell interactions, genetic and epigenetic alterations and cellular interactions. Then we
move back closer to clinical concerns with Chapters 7 and 8 that focus on biomarkers
and medical imaging. The last four chapters are dedicated to therapeutics. Chapter 9 deals
with the main concepts of NPC radiotherapy in terms accessible for the laymen. Chapter
10 provides an integrated view of all aspects of the medical or systemic treatments of
NPC. Chapter 11 focuses on NPC immunotherapy which is currently a very dynamic
field. The last chapter on therapeutic induction of apoptosis opens perspectives for novel
targeted therapies of NPC.
Finally I want to acknowledge all authors who did their best to go beyond their own
research interest and provide a comprehensive view of their subject. However many
aspects remain to be improved. All remarks and suggestions from the readers will be
welcomed ([email protected]).
Pierre Busson, MD, PhD
CNRS Director of Research
Université Paris-Sud 11
CNRS and Institut de Cancérologie Gustave Roussy, UMR 8126
Villejuif, France
ABOUT THE EDITOR...
PIERRE BUSSON is a Senior Research Scientist at the CNRS (National Center
for Scientific Research) and the Gustave Roussy Institute in Villejuif, close to Paris. He
obtained his MD in 1983 and his PhD in Virology in 1990 from Paris University. Following
a post-doctoral research fellowship at the Lineberger Cancer Research Center (Chapel
Hill, North Carolina, USA), he was recruited by the CNRS in 1992 and established his
own group in the Gustave Roussy Institute in 2001.
His major research interests are cellular interactions in Epstein-Barr virus-associated
nasopharyngeal carcinomas, with special emphasis on the role of tumor exosomes and
other secreted nano-objects, in a perspective of translational research. Recently, his group
has extended the same type of approach to ovarian carcinomas. He published about 75
articles in peer-reviewed scientific journals.
Dr Pierre Busson has been member of the Board of the International Association
for Epstein-Barr virus research from 2000 to 2004. He has been actively involved in the
organization of bi-annual international meetings on nasopharyngeal carcinomas (2003,
Villejuif; 2005, Toronto; 2007, Brisbane; 2009, Marrakech; 2011, Penang). He is a grant
reviewer for several institutions in France, Europe and in Hong-Kong. He is academic
editor for PLoS One and reviewer for about 20 journals.
ix
PARTICIPANTS
Carlo Bastianutto Grace Tin-Yun Chung
Department of Medical Biophysics Department of Anatomical
University of Toronto and Cellular Pathology
Toronto, Ontario State Key Laboratory in Oncology
Canada in Southern China
The Chinese University of Hong Kong
François Bidault Hong Kong
Radiology Department China
Institut de Cancérologie Gustave Roussy
Villejuif Bing-Jian Feng
France Department of Dermatology
University of Utah School of Medicine
Pierre Busson Salt Lake City, Utah
Université Paris-Sud 11 USA
CNRS and Institut de Cancérologie
Gustave Roussy, UMR 8126 François-Régis Ferrand
Villejuif Université Paris-Sud 11
France CNRS and Institut de Cancérologie
Gustave Roussy, UMR 8126
Anthony T.C. Chan Villejuif
Department of Clinical Oncology and
State Key Laboratory in Oncology Ecole du Val de Grâce
in South China Paris
Sir YK Pao Centre for Cancer France
and
Hong Kong Cancer Institute Luc Friboulet
Prince of Wales Hospital Université Paris-Sud 11
The Chinese University of Hong Kong Inserm U981 and Institut de Cancérologie
Hong Kong Gustave Roussy
China Villejuif
France
xi
